Focus: Alvotech is a public Luxembourg-based biotechnology company specializing in biosimilar development across immunology, neurology, gastroenterology, and ophthalmology. It operates as a mid-cap biotech with a commercial-stage pipeline and two FDA-approved biosimilar products on the market.
Profile data last refreshed 9h ago · AI intelligence enriched 2w ago
Growing — net +8 jobs in 30d
39 jobs added vs 31 removed. Steady team buildout.
Alvotech offers growth-stage biotech experience in a regulated, commercial-stage biosimilar company, but career trajectory depends on successful Phase 3 launches and post-LOE competitive positioning.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
First-to-market adalimumab biosimilar, addressing $10B+ reference product market; FDA-approved BLA supporting commercial uptake.
Help build intelligence for Alvotech
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Alvotech's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Second marketed biosimilar targeting IL-12/IL-23 pathway; addresses growing psoriasis and immunology biosimilar market.
8-K Filing: Amneal Pharmaceuticals, Inc. (AMRX) (CIK 0001723128) — EXHIBIT 99.2
EXHIBIT 99.2
FDA Clears Alvotech Process to More Than Double Simlandi Drug Substance Output - TOKENPOST
FDA Clears Alvotech Process to More Than Double Simlandi Drug Substance Output TOKENPOST
Alvotech wins FDA nod for higher SIMLANDI batch output - Mugglehead Investment Magazine
Alvotech wins FDA nod for higher SIMLANDI batch output Mugglehead Investment Magazine
Alvotech shares surge following second FDA approval - Iceland Monitor
Alvotech shares surge following second FDA approval Iceland Monitor
Alvotech and Advanz Pharma File First Known EMA Biosimilar Application for Eylea 8 mg - TipRanks
Alvotech and Advanz Pharma File First Known EMA Biosimilar Application for Eylea 8 mg TipRanks
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg - Yahoo Finance UK
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg Yahoo Finance UK
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Efficacy and Safety of Biosimilar AVT05 Versus Reference Product Golimumab in Combination with Methotrexate in Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results of a Randomized, Parallel-Group, Double-Blind Study.
Pharmacokinetic Similarity of Biosimiliar AVT05 Versus Reference Product Golimumab in Healthy Adults: A Double-Blind, Three-Arm, Parallel-Group Study.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo